PharmaMar today announced the successful planned review by the Independent Data Monitoring Committee (IDMC) of the YONDELIS® (trabectedin) Phase III pivotal clinical trial in ovarian cancer, known as OVA-301. The IDMC recommended that the present study should continue without modification.
